InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system.

Initially, IRT is based on two main components. On the one hand, it is a fully-fledged database including a wide variety of features covering the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated sub-models exported from IRT as building blocks to simplify the model development process.

IRT is a part of InSysBio’s QSP software infrastructure being under constant upgrade. IRT v.3.6.3 gets a range of new features:

• Model of B cell lifecycle was updated.
• New cell types were added:  Germinal center B cells (GC_B), effector B cells (efB), Germinal center plasma cells (gcPC), B memory cells activated (Bmem_a), long-lived plasma cells (LLPC).
• The velocity equations were expanded, modifiers were added: T helper cells (Th), CCL13, CCL20, Dendric cells activated (cDCa, MoDCa).

Veronika Musatova, Head of IRT development team, comments on the new version, “As a result of the update, B cells model reflects the current views on the processes and sequence of this cell type development maintaining a balance between the model detail and complexity.”

To learn the full content of Immune Response Template, please visit irt.insysbio.com.

To get demo access to IRT, please click “sign in” or “user account” on the irt.insysbio.com.

To get more information on any tool or leave your feedback, please feel free to contact us: support@insysbio.com

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share